
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is a biopharmaceutical company with a robust portfolio of gene therapy platforms and clinical programs targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company's lead product, Papzimeos, showed durable complete responses after a single treatment in a pivotal study with no reported safety issues. In addition, the FDA granted Papzimeos orphan-drug market exclusivity in adult RRP, providing a competitive advantage in a small rare-disease market. With positive ASCO durability data and an upcoming PRGN-2009 Phase 2 update, the company is well-positioned for continued success and potential future growth.
Bears say
Precigen is facing significant risks and challenges, including clinical and regulatory hurdles in developing and commercializing their gene therapy products. Despite potential label expansion opportunities, the company has yet to generate positive earnings and has a high debt level. Furthermore, the success of their products ultimately depends on obtaining regulatory approvals and maintaining successful partnerships, which are key areas of risk for the company.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares